Skip to NavigationSkip to content

Johnson & Johnson

J&J vaccine halted in US due to blood clots

Johnson & Johnson sign

The CDC and FDA have recommended a pause in the use of the Johnson & Johnson COVID-19 vaccine in the US, over fears that the shot may cause blood clotting.

J & J to ship up to 400 million vaccines to Africa

COVID-19 vaccines

Johnson & Johnson has reached an agreement to ship as many as 400 million doses of their COVID-19 vaccine to African Union (AU) member states.

AstraZeneca and J&J COVID-19 vaccines face viral vector shortage

Photo by Nataliya Vaitkevich from Pexels

Both AstraZeneca and J&J face major manufacturing deficiencies for their recombinant vector COVID-19 vaccines, forcing competition over limited production capacity for gene and gene-modified cell therapies, according to GlobalData.

The recombinant vector vaccines use an attenuated virus to introduce microbial DNA to cells of the body, a different molecule type from those used in the mRNA-based vaccines from Pfizer/BioNTech and Moderna.

Johnson & Johnson’s arthritis drug shows promising results in Phase III trial

Janssen sign

Johnson & Johnson’s TREMFYA treatment for active Psoriatic Arthritis (PsA) has returned positive results in its Phase III trial.

J&J’s one-shot COVID-19 vaccine approved by European Commission

The European Commission has granted Johnson and Johnson’s single-shot COVID-19 vaccine Conditional Marketing Authorisation (CMA), it was announced on Thursday.

J&J have committed to supply 200 million doses in 2021 and will begin delivery of the vaccine to the EU in the second half of April.

Data from the Phase III study showed that the one-shot vaccine caused a 67% reduction in symptomatic COVID-19 disease in participants who received the vaccine versus patients given the placebo.

FDA approves Johnson & Johnson's COVID-19 vaccine for emergency use

The FDA has issued emergency use authorisation for Johnson & Johnson’s one-shot COVID-19 vaccine, approving the jab for use in individuals aged 18 and older in the US.

The agency’s decision was based on the totality of scientific evidence, including data from the Phase III ENSEMBLE study that demonstrated the vaccine was 85% effective in preventing severe disease, and showed protection against COVID-19 related hospitalisation and death from 28 days after vaccination.

J&J’s one-shot COVID-19 vaccine submitted to the EU

johnson and johnson sign

Johnson & Johnson has applied to the EMA for marketing authorisation of their one-shot COVID-19 vaccine in Europe.

Johnson & Johnson's single-shot COVID-19 vaccine 85% effective

Johnson & Johnson has announced that its COVID-19 vaccine candidate is 85% effective in preventing serious symptoms of the disease, after interim analysis of Phase III of its trial.

The shot, which was also 66% successful in preventing moderate to severe COVID-19, only requires one dose rather than two - unlike other vaccines such as the Oxford University/AstraZeneca vaccine currently being administered in the UK.

New Johnson & Johnson study aiming to add stroke detection to Apple Watch

Johnson & Johnson announced that Janssen Pharmaceuticals will work in collaboration with Apple to explore apps for stroke detection.

It is designed to explore if the Heartline Study app on Apple Watch and iPhone, with its heart health features, can improve health outcomes which includes reducing the risk of stroke. It will achieve this by attempting to detect atrial fibrillation (AFib), a common form of irregular heart rhythm, and a leading cause of stroke, much earlier.

Jury orders Johnson & Johnson to pay $750 million in latest baby powder case

Johnson & Johnson have been ordered to pay by a jury $750 million to four plaintiffs over the company’s baby powder product being alleged to contained carcinogens.

The jury concluded that the company had not properly informed consumers of the risk of using the powder. Traces of the carcinogen asbestos can found in talc and can cause mesothelioma.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches